[1] |
Tan WC, Mahayiddin AA, Charoenratanakul S, et al.Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (UPDATE 2014) global initiative for chronic obstructive lung disease 2014 GOLD[J].Respirology, 2005, 10 (1): 9-17.
|
[2] |
Dalal AA, Shan M, Lunacsek O, et al.Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease[J].Respir Med, 2011, 105 (10): 1516-1522.
|
[3] |
Soriano JB, Lamprecht B.Chronic obstructive pulmonary disease: a worldwide problem[J].Med Clin North Am, 2012, 96 (4): 671-680.
|
[4] |
Furguson GT, Anzueto A, Fei R, et al.Effect of fluticasone proprionate/salmeterol (250/500 μg) or salmeterol (50μg) on COPD exacerbations[J].Respir Med, 2008, 102 (8): 1099-108.
|
[5] |
Tashkin DP, Celli B, Senn S, et al.A 4-year trial of tiotropium in chronic obstructive pulmonary disease[J].N Engl J Med, 2008, 359 (8): 1543-1554.
|
[6] |
Niewoehner DE, Rice K, Cote C, et al.Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily anticholinergic brochodilator[J].Ann Intern Med, 2006, 143 (5): 317-326.
|
[7] |
Drummond MB, Dasenbrook EC, Pitz MW, et al.Inhaled corticosteroids in patients with Stable chronic obstructive pulmonary disease:a systematic review and meta-analysis)[J].JAMA, 2008, 300 (20): 2407-2416.
|
[8] |
Brassard P, Suissa S, Kezouh A, et al.Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases[J].Am J Respir Crit Care Med, 2011, 183 (5): 675-678.
|
[9] |
Lapi F, Kezouh A, Suissa S, et al.The use of inhaled corticosteroids and the risk of adrenal insufficiency[J].Eur Respir J, 2013, 42 (1): 79-86.
|
[10] |
CHMP recommends refusal of nerventra marketing authorisation[J].Reactions Weekly, 2014, 1488 (1): 2
|
[11] |
Vogel HG, Maas J, Hock FJ, et al.Drug discovery and evaluation: safety and pharmacokinetic assays[M].Berlin Heidelberg: Springer, 2013: 847-850.
|
[12] |
Amschler H.Fluoroalkoxy-Substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors: US, US5712298[P].1998.
|
[13] |
Jadad AR, Moore RA, Carroll D.Accessing the quality of reports of randomized clinical trials: is blinding necessary?[J].Controlled Clinical Trials, 1996, 17 (1): 1-12.
|
[14] |
Shuster JJ.Review: Cochrane handbook for systematic reviews for interventions, Version 5.1.0, published 3/2011.Julian P.T. Higgins and Sally Green, Editors[J].Research Synthesis Methods, 2011, 2(2): 126-130.
|
[15] |
Liberati A, Altman DG, Tetzlaff J, et al.The PRISMA statement for reporting systematic reviews and meta-analysis of studies that evaluate healthcare interventions: explanation and elaboration[J]. BMJ, 2009, 339 (10): e1-e34.
|
[16] |
Rabe KF, Bateman ED, O'Donnell D, et al.Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial[J].Lancet, 2005, 366 (2): 563-571.
|
[17] |
Calverley PM, Sanchez-Toril F, McIvor A, et al.Effect of 1-Year treatment with roflumilast in severe chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med, 2007, 176 (2): 154-161.
|
[18] |
Calverley PM, Rabe KF, Goehring UM, et al.Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials [J].Lancet, 2009, 374 (9691): 685-694.
|
[19] |
Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al.Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials[J].Lancet, 2009, 374 (9691): 695-703.
|
[20] |
Rennard SI, Calverley PM, Goehring UM, et al.Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD[J].Respiratory Research, 12 (1): 176-180.
|
[21] |
Lee SD, Hui DSC, Mahayiddin AA, et al.Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial[J].Respirology, 2011, 16 (8): 1249-1257.
|
[22] |
Zheng JP, Kang J, Zhong NS, et al.Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study[J].CHEST, 2014, 145 (1): 44-52.
|
[23] |
Szafranski W, Cukier A, Ramirez A, et al.Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease[J].Eur Respir J, 2003, 21 (1): 74-81.
|
[24] |
Bundschuh DS, Eltze M, Barsig J, et al.In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor[J].J Pharmacol Exp Ther, 2001, 297 (1): 280-290.
|
[25] |
Boswell-Smith V, Spina D.PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast[J].Int J COPD, 2007, 2 (2): 121-129.
|
[26] |
Barnes PJ, Shapiro SD, Pauwels RA.Chronic obstructive pulmonary disease: molecular and cellular mechanisms[J]. Eur Respir J, 2003, 22 (4): 672-688.
|
[27] |
Perera WR, Hurst JR, Wilkinson TM, et al.Inflammatory changes, recovery and recurrence at COPD exacerbation[J].Eur Respir J, 2007, 29 (3): 527-534.
|
[28] |
Halpin DM, Tashkin DP.Defining disease modification in chronic obstructive pulmonary disease[J].COPD, 2009, 6 (3): 211-225.
|
[29] |
Mahler DA, Weinberg DH, Wells CK, et al.The measurement of dyspnea, contents, interobserver agreement, and physiologic correlates of two new clinical indexes[J].Chest, 1984, 85 (6): 751-758.
|
[30] |
O'Donnell DE.Breathlessness in patients with chronic airflow limitation: mechanisms and management[J].Chest, 1994, 106 (3): 904-912.
|
[31] |
Jaeschke R, Singer J, Guyatt GH.Measurement of health status.Ascertaining the minimal clinically important difference[J].Control Clin Trials, 1989, 10 (4): 407-415.
|
[32] |
Cazzola M, MacNee W, Martinez FJ, et al.Outcomes for COPD pharmacological trials: from lung function to biomarkers[J].Eur Respir J, 2008, 31 (2): 416-469.
|
[33] |
Calverley PM.Minimal clinically important difference-exacerbation of COPD[J].COPD, 2005, 2 (1): 143-148.
|
[34] |
Witek TJ, Mahler DA.Minimal important difference of the transition dyspnoea index in a multinational clinical trial[J]. Eur Respir J, 2003, 21 (2): 267-272.
|
[35] |
Giembycz MA, Newton R.Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies[J].Handb Exp Pharmacol, 2011, 204: 415-446.
|
[36] |
Newton R, Leigh R, Giembycz MA.Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases[J].Pharmacol Ther, 2010, 125 (2): 286-327.
|
[37] |
King EM, Chivers JE, Rider CF, et al.Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation- and transrepression-dependent mechanisms[J].PLoS One, 2013, 8 (1): 173-185.
|
[38] |
Milara J, Lluch J, Almudever P, et al.Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease[J].J Allergy Clin Immunol, 2014, 134 (2): 314-322.
|